以吡柔比星为主的新辅助化疗结合手术治疗乳腺癌的临床观察

目的探讨乳腺癌新辅助化疗的可行性和不良反应。方法45例乳腺癌患者接受以吡柔比星（THP）50mg/m^2为主的术前化疗2个周期,化疗结束后5～7 d天再予手术（试验组）。39例乳腺癌患者同期直接手术（对照组）。结果试验组化疗总有效率为77.7%（35/45）;两组的手术难度、手术时间、术中出血量及术后引流量差异均无显著性（P〉0.05）。结论对可手术乳腺癌患者行术前新辅助化疗可使原发病灶缩小,减少手术范围,提高患者术后生活质量;不增加手术并发症,可望提高疗效。

Clinical observation on new adjuvant chemotherapy with THP-containing regimen combined with surgery for treatment of breast cancer

Objective To explore the feasibility and adverse reactions of the new adjuvant chemotherapy for breast cancer. Methods Forty-five breast cancer patients accepted preoperative chemotherapy with THP 50 mg/m^2-containing regimen for two cycles, and accepted operation after five to seven days （ test group）. Thirty-nine breast cancer patients accepted direct operation in the same period （ control group ）. Results The total efficacy of the chemotherapy test group was 77. 7% （35/45）, and there was no significant difference between the two groups in difficulty of operation, operation time, blood loss and postoperative drainage volume （P 〉 0. 05）. Conclusion New adjuvant chemotherapy for the operable breast cancer patients before operation can reduce the size of the focus and the scope of operation, improve the quality of life, and does not increase the operative complications. Thus, it is expected to increase efficacy.